---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-005110"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:16:05.679074+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeuroBo reports FY2022 net loss $14.0M; cash $33.4M; pipeline shift to cardiometabolic

## Summary
- Net loss of $14.0M ($5.43 per share) vs $15.3M ($19.81 per share) in FY2021.
- Cash and equivalents $33.4M as of Dec 31, 2022, up from $16.4M; runway into 2024.
- R&D expenses fell to $2.8M from $6.5M due to reduced clinical activity and drug manufacturing.
- Pipeline focus: DA-1241 phase 2a NASH study starts Q3 2023; DA-1726 IND/phase 1a expected H1 2024.
- Legacy programs (ANA001, NB-01, NB-02, Gemcabene) to be licensed or acquired.

## SEC filing metadata
- accession: 0001558370-23-005110
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837023005110/0001558370-23-005110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837023005110/nrbo-20230330x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-005110
- JSON: https://secwatch.observer/filing/0001558370-23-005110.json
- Plain text: https://secwatch.observer/filing/0001558370-23-005110.txt

## Key facts
- Earnings Releases
  MetaVia Inc. reported year ended December 31, 2022 results: net income Net Loss for the year ended December 31, 2022 was $14.0 million, EPS $5.43 per basic and diluted share.
  - Period: year ended December 31, 2022
  - Net income: Net Loss for the year ended December 31, 2022 was $14.0 million
  - EPS: $5.43 per basic and diluted share
  - Result: reported results
  source text: Net Loss for the year ended December 31, 2022 was $14.0 million, or $ 5.43 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000155837023005110/0001558370-23-005110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.